Abstract：
:Over the past 30 years there has been an increased use of neoadjuvant (or primary) chemotherapy for treating patients with breast cancer. However, while it is clear that chemotherapy given in the adjuvant setting after surgery does prolong patients' overall and disease-free survival, the evidence that chemotherapy in the neoadjuvant setting also increases survival remains unproven. In the Aberdeen study, 162 patients with large and locally advanced breast cancer underwent 4 cycles of CVAP (cyclophosphamide/vincristine/doxorubicin/prednisone) primary chemotherapy. Patients with a complete or partial response were then randomized to either 4 further cycles of CVAP or 4 cycles of docetaxel (100 mg/m2). It was shown that the addition of sequential docetaxel (100 mg/m2) to CVAP neoadjuvant chemotherapy resulted in a significantly enhanced clinical response rate (94% vs. 64%) and a substantially increased complete histopathological response rate (34% vs. 16%) when compared to patients receiving CVAP alone. Furthermore, patients receiving docetaxel had an increased breast conservation rate (67% vs. 48%) and an increased survival at a median follow-up of 3 years. It is important to note that this was a small study, and the survival results should be interpreted with caution. The results are encouraging, however, and further studies are urgently required.
journal_name
Clin Breast Cancerjournal_title
Clinical breast cancerauthors
Heys SD,Hutcheon AW,Sarkar TK,Ogston KN,Miller ID,Payne S,Smith I,Walker LG,Eremin O,Aberdeen Breast Group.doi
10.3816/cbc.2002.s.015keywords:
subject
Has Abstractpub_date
2002-10-01 00:00:00pages
S69-74eissn
1526-8209issn
1938-0666pii
S1526-8209(11)70292-0journal_volume
3 Suppl 2pub_type
临床试验,杂志文章,随机对照试验abstract：:Pathologic complete remission after neoadjuvant chemotherapy has a role in guiding the management of breast cancer. The present meta-analysis examined the accuracy of contrast-enhanced magnetic resonance imaging (CE-MRI) and diffusion-weighted magnetic resonance imaging (DW-MRI) in detecting the response to neoadjuvan...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clbc.2016.12.010
更新日期：2017-07-01 00:00:00
abstract：BACKGROUND:The ExteNET trial demonstrated improved invasive disease-free survival (iDFS) with neratinib, an irreversible pan-HER tyrosine kinase inhibitor, versus placebo in patients with human epidermal growth factor receptor 2-positive (HER2+)/hormone receptor-positive (HR+) early-stage breast cancer (eBC). PATIENTS...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2020.09.014
更新日期：2020-10-06 00:00:00
abstract：AIM:Our study was to investigate the heterogeneity of estrogen receptor (ER) expression among tumor sites by using fluorine-18 ((18)F) fluoroestradiol (FES) positron-emission tomography-computed tomography (PET-CT) imaging. METHODS:Thirty-two breast cancer patients underwent both (18)F-FES and (18)F fluorodeoxyglucose...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2013.02.012
更新日期：2013-10-01 00:00:00
abstract：:Chyle fistula is not a well-known complication of axillary dissection in patients with breast cancer. Although rare, this complication can occur as a result of anatomic variation of the thoracic duct and its venous anastomosis. Injury to the lateral terminating branches or lymphatic trunk, leading to retrograde chyle ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2006.n.030
更新日期：2006-06-01 00:00:00
abstract：BACKGROUND:Studies have shown that young patients with early-stage breast cancer (BC) are increasingly undergoing mastectomy instead of breast-conserving therapy (BCT) consisting of lumpectomy and radiation. We examined the difference in outcomes in young women (aged < 40 years) who had undergone BCT versus mastectomy....
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2015.03.012
更新日期：2015-10-01 00:00:00
abstract：INTRODUCTION:The purpose of this study was to evaluate the added value of breast magnetic resonance imaging (MRI) in preoperative diagnosis of ductal carcinoma in situ (DCIS). We reviewed our institution database of 3499 consecutive patients treated for breast cancer. PATIENTS AND METHODS:A total of 362 patients with ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2016.12.007
更新日期：2017-06-01 00:00:00
abstract：BACKGROUND:Letrozole withdrawal for 3 months might permit estrogenic stimulation in residual resistant breast cancer disease susceptible to letrozole reintroduction. We investigated the impact of a 3-month letrozole-free interval on serum estradiol levels in patients with early stage breast cancer. PATIENTS AND METHOD...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2015.03.007
更新日期：2015-10-01 00:00:00
abstract：INTRODUCTION:Breast cancer (BC) is the most common cancer in women, and the incidence of brain metastasis (BM) from BC ranges from 20% to 30%, with a median survival of 10 to 15 months. Previous reports have shown that the presence of obesity or diabetes negatively impacts survival. The present study investigates the a...
journal_title：Clinical breast cancer
pub_type： 杂志文章,多中心研究
doi：10.1016/j.clbc.2018.12.018
更新日期：2019-04-01 00:00:00
abstract：BACKGROUND:Nipple-sparing mastectomies (NSMs) preserve the intact nipple, including nipple duct orifices. Retained orifices might remain patent and communicate with the underlying reconstruction. We report the incidence and outcomes of nipple discharge after NSM in pregnant and nonpregnant women. PATIENTS AND METHODS:...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2019.03.003
更新日期：2019-08-01 00:00:00
abstract：BACKGROUND:Medical isotopes are required for sentinel node lymphoscintigraphy in breast cancer, but are in critical shortage. Our center uses a modification of the standard SC, called CRC, that has been shown to require less medical isotope for the same procedure. Our objective was to determine if there was a significa...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2014.07.006
更新日期：2015-02-01 00:00:00
abstract：:Chemotherapeutic agents that disrupt the assembly or disassembly of microtubules, including paclitaxel and docetaxel, are among the most commonly prescribed anticancer therapies. However, the utility of taxane-based therapy is limited principally by problems with formulation, slow administration, cumulative neurotoxic...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2008.s.001
更新日期：2008-03-01 00:00:00
abstract：BACKGROUND:Most investigations have compared triple-negative breast cancer (TNBC) to non-TNBC to elucidate clinical or epidemiologic differences between subtypes. We examined a contemporary cohort of patients with primary TNBC by detection and age at diagnosis within a population-based breast screening program to exami...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2018.04.013
更新日期：2018-10-01 00:00:00
abstract：INTRODUCTION:For patients who have an ipsilateral breast cancer recurrence following prior breast-conserving surgery and radiation, total mastectomy generally is recommended. However, little is known about the suitability and outcomes of nipple-sparing mastectomy (NSM) with immediate breast reconstruction for the treat...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2016.10.011
更新日期：2017-07-01 00:00:00
abstract：:Breast cancer is the second leading cause of cancer death in women, affecting 1.7 million patients every year worldwide. As a result of its heterogeneous nature, the genetic profile and associated clinical feature varies greatly among different breast cancer subtypes. With the advancement of molecular biology, our und...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clbc.2016.05.012
更新日期：2016-10-01 00:00:00
abstract：:The management of metastatic breast cancer is changing as a consequence of extraordinary discoveries in cancer research and the development of more advanced diagnostic technologies. Although traditional chemotherapeutics such as anthracyclines and taxanes still represent the mainstay of treatment for this disease, new...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/CBC.2001.n.002
更新日期：2001-01-01 00:00:00
abstract：BACKGROUND:Flow cytometry (FCM) evaluating DNA content is emerging as the tool to monitor cell proliferation and malignant potential in several cancers such as stomach, lung, and salivary gland tumor. The purpose of this study was to correlate (18)F-FDG uptake of dual-time-point (DTP) positron emission tomography (PET)...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2012.09.010
更新日期：2013-06-01 00:00:00
abstract：BACKGROUND:The objective of the study was to compare the accuracy of different magnetic resonance (MR) sequences for measuring tumor size and to evaluate whether the imaging and histopathologic features affect the accuracy of the tumor size estimation on the MR sequence. PATIENTS AND METHODS:Eight hundred women were i...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2016.07.007
更新日期：2016-12-01 00:00:00
abstract：:This article attempts to provide the reader with a complete overview of topoisomerase (topo) II alpha as a marker for predicting the efficacy of anthracyclines in patients with breast cancer. In the first section of this article, in vitro data supporting the predictive value of topo II alpha are reviewed. Interestingl...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：
更新日期：2003-08-01 00:00:00
abstract：INTRODUCTION:The adjuvant trastuzumab trials largely excluded women with small, node-negative, HER2-positive breast cancers. Accordingly, limited data exist regarding the effect of trastuzumab in the management of these patients. Our aim was to assess the outcomes of, and treatments administered to, women with small (≤...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2014.12.012
更新日期：2015-08-01 00:00:00
abstract：BACKGROUND:Nanoparticle albumin-bound paclitaxel (nab-P) and bevacizumab have each demonstrated efficacy in patients with MBC. This trial was designed to further develop nab-P by evaluating its efficacy and safety using every 3 weeks (q3w), every 2 weeks (q2w), or weekly scheduling in combination with bevacizumab as fi...
journal_title：Clinical breast cancer
pub_type： 杂志文章,随机对照试验
doi：10.1016/j.clbc.2013.02.008
更新日期：2013-08-01 00:00:00
abstract：BACKGROUND:Triple-negative breast carcinoma is defined by a primary tumor that is estrogen receptor negative, progesterone receptor negative, and HER2 negative. The current study was performed to determine the relationship of triple-negative tumor status to outcome after breast conservation treatment with radiation. P...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2009.n.018
更新日期：2009-05-01 00:00:00
abstract：:Fulvestrant, an estrogen receptor antagonist that downregulates the estrogen receptor but has no known agonist effects, has been evaluated in 2 randomized trials involving postmenopausal women with hormone receptor-positive, progressive advanced-stage breast cancer after disease progression with antiestrogen therapy. ...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2005.s.009
更新日期：2005-04-01 00:00:00
abstract：BACKGROUND:Activation of the JAK/STAT pathway is common in triple-negative breast cancer (TNBC) and affects the expression of genes controlling immune signaling. A subset of TNBC cases will have somatic amplification of chromosome 9p24.1, encoding PD-L1, PD-L2, and JAK2, which has been associated with decreased surviva...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2018.05.006
更新日期：2018-10-01 00:00:00
abstract：BACKGROUND:The study aimed to evaluate the feasibility and reliability of ultrasound-guided vacuum-assisted breast biopsy (US-VABB) for sampling of microcalcifications indicative of cancer when stereotactic vacuum-assisted breast biopsy cannot be performed because of reasons such as thin breast tissue, insufficient thi...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2018.12.002
更新日期：2019-04-01 00:00:00
abstract：:In a review of current information on aromatase inhibitors (AIs) and their use in breast cancer treatment and prevention, published reports were obtained through a Medline search. Tamoxifen, a selective estrogen receptor modulator, is approved for use in metastatic breast cancer (MBC), the adjuvant treatment of breast...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/CBC.2005.n.006
更新日期：2005-04-01 00:00:00
abstract：BACKGROUND:The [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) cancer screening program is defined as cancer screening for asymptomatic subjects using FDG-PET/computed tomography with or without combination of other screening tests. The aim of this study was to analyze the detection rate and effectivene...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2014.09.008
更新日期：2015-04-01 00:00:00
abstract：UNLABELLED:Analysis of magnetic resonance imaging-guided breast biopsies yielding high-risk histopathologic features at a single institution found an overall upstage rate to malignancy of 14% at surgical excision. All upstaged lesions were associated with atypical ductal hyperplasia. Flat epithelial atypia and atypical...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2014.12.005
更新日期：2015-06-01 00:00:00
abstract：BACKGROUND:Following treatment for breast cancer, many young women are interested in having a child. There are few data available regarding actual fertility and menopausal outcomes in young breast cancer survivors. We evaluated these outcomes among young breast cancer survivors in collaboration with the Young Survival ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2008.n.004
更新日期：2008-02-01 00:00:00
abstract：:The histopathologic subtypes of breast cancer, including invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), differ in terms of risk factors, progression, and response to treatment. The PubMed/Medline, Web of Science, and Scopus databases were searched up to February 2020 for published studies on the...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clbc.2020.03.007
更新日期：2020-08-01 00:00:00
abstract：BACKGROUND:Although brain metastases (BM) are associated with poor prognosis, patients with human epidermal growth factor receptor 2 (HER2) overexpressing (HER2+) breast cancer (BC) with BM who are treated with anti-HER2 therapy have a relatively longer survival after BM diagnosis compared with other subtypes and HER2+...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2017.12.009
更新日期：2018-10-01 00:00:00
